Compare AIP & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIP | VALN |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 687.6M | 820.0M |
| IPO Year | 2021 | 2021 |
| Metric | AIP | VALN |
|---|---|---|
| Price | $15.57 | $8.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $16.30 | $15.75 |
| AVG Volume (30 Days) | ★ 651.8K | 20.4K |
| Earning Date | 02-17-2026 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $65,931,000.00 | ★ $211,089,992.00 |
| Revenue This Year | $20.67 | $3.64 |
| Revenue Next Year | $20.20 | $12.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.45 | 13.48 |
| 52 Week Low | $5.46 | $4.02 |
| 52 Week High | $19.85 | $12.25 |
| Indicator | AIP | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 49.20 | 44.24 |
| Support Level | $15.44 | $8.27 |
| Resistance Level | $16.41 | $8.97 |
| Average True Range (ATR) | 0.92 | 0.31 |
| MACD | -0.22 | 0.03 |
| Stochastic Oscillator | 13.29 | 31.48 |
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.